Caplacizumab (Cablivi) for iTTP

Date: October 19, 2020 Issue #:  1609Summary:  Caplacizumab-yhdp (Cablivi– Sanofi /Genzyme), a von Willebrand factor-directed antibody fragment, has been approved by the FDA for use in combination with plasma exchange and immunosuppressive therapy for treatment of immune-mediated thrombotic thrombocytopenic purpura (iTTP; formerly called acquired thrombotic thrombocyto penic purpura [aTTP]) in adults. It is the first drug to be approved in the US for this indication.
Source: The Medical Letter - Category: Drugs & Pharmacology Authors: Source Type: research